Duchesnay's new nod for menopause drug Osphena prompts website revamp

Woman iPhone doctor
Women facing symptoms of menopause can look to Duchesnay's new Osphena website for explainers and information. (Getty/RossHelen)

In January, Duchesnay’s Osphena got the FDA nod to treat moderate to severe vaginal dryness caused by vulvar and vaginal atrophy (VVA) in menopausal women, adding to the drug’s original approval to treat dyspareunia or painful intercourse among the same group. And now, the new indication has inspired a new website for the menopause drug.

The new site offers expanded information and a better user experience with faster downloads, more intuitive navigation and more colorful visuals, Melanie Lussier, Duchesnay's vice president of corporate affairs and communications, said in an email interview.

RELATED: Pfizer turns the sex talk toward 50-ish women with menopause awareness push

On the website, Duchesnay features three videos from its new paid spokesperson gynecologist Barb Dupree talking about the causes and signs around the vaginal symptoms of menopause. As an adjunct, Duchesnay is currently analyzing data from a recent study it did in partnership with FabOverFifty.com about treatment preferences for women experiencing menopause symptoms such as vaginal dryness. Those results will be released next month, Lussier said.

Duchesnay acquired the rights to market Osphena in the U.S. and Canada from Shionogi in March 2017. The drug has a boxed warning regarding endometrial cancer and cardiovascular disorders. Shionogi spent millions trying to spur the market for Osphena—including $38 million in TV ads alone, according to real-time TV ad tracker iSpot.tv data—before selling it to Duchesnay.

RELATED: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points

Osphena was first approved in 2013 and at the time, analysts pegged peak sales at $495 million by 2017. Duchesnay is a private company and does not report sales publicly, but its website says the drug has been prescribed “over 1 million times since its launch in 2013.”

While Osphena is a non-hormonal product, its primary competition is low-dose estrogen creams and vaginal rings including Allergan's Estrace, Pfizer's Premarin and Novo Nordisk's Vagifem.

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.